The Frequency of BCR-ABL1 Fusion Transcripts in Iranian Patients with Three Different Types of Leukemia

Hamid, Mohammad; Bokharaei, Hanieh

doi:10.5812/zjrms.10197

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Al‐Achkar, Moassass, Youssef, and Wafa (), Hanfstein et al () and Hamid and Bokharaei () did not catch any association between gender and BCR‐ABL transcripts. Furthermore, other studies registered reversed setting, that is, b3a2 transcript was more common in females and b2a2 transcript was more common in males.…”

Section: Discussionmentioning

confidence: 93%

Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients

Khazaal

Hamdan

Al-Mayah

2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of BCR‐ABL fusion gene (GenBank accession ). In the vast majority of CML patients, the typical subtype of BCR‐ABL transcript are b3a2, b2a2 or both. The aim of this study was to determine the different subtypes of BCR‐ABL transcript and their impact on the demographic and hematological parameters in Iraqi patients with CML. Methods One hundred patients with chronic phase CML (11 newly diagnosed and 89 imatinib‐resistant) were enrolled in this study. Ribonucleic acid (RNA) was extracted from leukocytes, and complementary DNA was created using reverse transcriptase polymerase chain reaction technique. A multiplex polymerase chain reaction with four specific primers was used to determine the BCR‐ABL fusion subtypes in each patient. Results Male to female ratio was 1.38:1. Fifty‐nine patients expressed b3a2 transcript, whereas 39 of the remaining cases were positive for b2a2 variant. One case expressed b2a3 transcript, while the last case coexpressed the two subtypes of mRNA b3a2/b2a2. Male and female were significantly associated with b3a2 and b2a2 subtypes, respectively. The b3a2 subtype showed higher total leukocyte count than b2a2 subgroup, while b2a2 variant demonstrated significantly elevated platelet counts compared to those with b3a2 transcript. A significantly higher plateletcrit percentage (PCT%) was found in patients with b2a2 transcript whereas. Conclusions The testified Iraqi group expressed M‐BCR‐ABL type with preponderance of b3a2 over b2a2 subtype. There was a gender‐skewed distribution in BCR‐ABL transcript types with b3a2 transcript more prevalent in males. The type of BCR‐ABL transcript is reflected by different leukocyte and platelet counts at diagnosis, which might represent a distinct phenotype and disease biology.

show abstract

Section: Discussionmentioning

confidence: 93%

Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients

Khazaal

Hamdan

Al-Mayah

2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

show abstract

“…The frequency of BCR ABL gene in acute lymphoblastic leukemia in our study population is comparable to international studies. [8][9][10][11][12][13] However, it is the largest first-ofits-kind study in Pakistan, conducted in AFIP center.…”

Section: Discussionmentioning

confidence: 99%

“…7 Another study was conducted at Pasteur Institute Iran on 72 patients of ALL in which 9 (12.5%) patient of ALL were positive for BCR-ABL gene rearrangement. 8 These studies being conducted on small sample size showed variation in the results hence we carried out our study in our institute on a large sample size to see the frequency of BCR-ABL gene mutation in diagnosed patients of acute lymphoblastic leukemia.…”

Section: Original Articlementioning

confidence: 99%

BCR-ABL1 Gene Mutation in Acute Lymphoblastic Leukemia

Haider¹,

Mahmood²,

Akhtar

et al. 2022

Ann Pak Inst Med Sci

View full text Add to dashboard Cite

Objective: Determination of frequency of BCR-ABL1 gene mutation in Acute Lymphoblastic Leukemia. Methodology: This cross sectional study was carried out at the Department of Molecular Haematology, Armed Forces Institute of Pathology between January 2018 to March 2021. All newly diagnosed patients of Acute Lymphoblastic Leukemia were included in the study while patients already on treatment and with secondary leukemia were excluded from the study. Blood counts were done and various parameters such as total leukocyte count, hemoglobin, and platelet count were calculated. Results: 623 patients were included in the study. BCR-ABL gene was positive in 105 (16.8%) patients. A total of 96 (92%) were positive for BCR ABL p190 rearrangement and 9 (8%) were positive for BCR ABL p210 rearrangement. Mean age of patients was 21 years. The frequency of BCR ABL gene was positive in 72% males and 28% females. BCR-ABL positive ALL was associated with higher TLC count. CNS involvement was more common in Acute Lymphoblastic Leukemia with BCR-ABL. The likelihood of post-induction remission decreased with age. Conclusion: In our study population, a frequency of 16.8% patients were BCR ABL1 positive in acute lymphoblastic leukemia. BCR- ABL gene mutation in ALL is more prevalent in young adults. The frequency of p190 rearrangement is more common than p210 BCR-ABL rearrangement. BCR-ABL positive ALL is more prevalent in males than in females.

show abstract

Imatinib and Patient-Related Outcomes in Chronic Myeloid Leukemia: A Single Centric Experience

Singh

Azharuddin

Agrawal

et al. 2022

SN Compr. Clin. Med.

View full text Add to dashboard Cite

The Frequency of BCR-ABL1 Fusion Transcripts in Iranian Patients with Three Different Types of Leukemia

Cited by 4 publications

References 15 publications

Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients

Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients

BCR-ABL1 Gene Mutation in Acute Lymphoblastic Leukemia

Imatinib and Patient-Related Outcomes in Chronic Myeloid Leukemia: A Single Centric Experience

Contact Info

Product

Resources

About